Nexalin rises after outlining steps toward FDA filing for Alzheimer’s device

Nexalin Technology

15/04/2026 15:07

** Shares of Nexalin Technology NXL.O rise 14% to $0.49

** The medical device maker says it met the U.S. FDA as it prepares an application to seek approval for its device to treat Alzheimer’s symptoms

** Adds that the FDA gave guidance on clinical trial design; Nexalin aims to submit an updated application in Q2 2026

** The device targets Alzheimer’s disease, a condition that slowly damages memory and thinking, by stimulating brain activity to improve cognitive function - NXL

** NXL says it also met U.S. academic researchers to refine its clinical and regulatory strategy

** Adds that in China studies led by an Alzheimer’s expert at a Beijing hospital add to one of its largest datasets in aging and dementia patients

** Nexalin’s non-invasive, drug-free device is already approved in China, Brazil, Oman and Israel - NXL

** Including session's move, stock down ~15%

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))